DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue S 2 · Volume 31 · July 1998 DOI: 10.1055/s-002-6334

Editorial

  • 61
    Gouzoulis-Mayfrank, E.; Sass, H.:

    Hallucinogenic Drugs in Experimental Psychiatric Research

    • Original Papers

  • 63
    Gouzoulis-Mayfrank, E.; Hermle, L.; Thelen, B.; Sass, H.:

    History, Rationale and Potential of Human Experimental Hallucinogenic Drug Research in Psychiatry

  • 69
    Kovar, K.-A.:

    Chemistry and Pharmacology of Hallucinogens, Entactogens and Stimulants

  • 73
    Geyer, M. A.:

    Behavioral Studies of Hallucinogenic Drugs in Animals: Implications for Schizophrenia Research

  • 80
    Dittrich, A.:

    The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans

  • 85
    Hermle, L.; Gouzoulis-Mayfrank, E.; Spitzer, M.:

    Blood Flow and Cerebral Laterality in the Mescaline Model of Psychosis

  • 92
    Vollenweider, F. X.:

    Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research

  • 104
    Abi-Saab, W. M.; D'Souza, D. C.; Moghaddam, B.; Krystal, J. H.:

    The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls

  • 110
    Schneider, U.; Leweke, F. M.; Mueller-Vahl, K. R.; Emrich, H. M.:

    Cannabinoid/Anandamide System and Schizophrenia: Is there Evidence for Association?

  • 114
    Gouzoulis-Mayfrank, E.; Schneider, F.; Friedrich, J.; Spitzer, M.; Thelen, B.; Sass, H.:

    Methodological Issues of Human Experimental Research with Hallucinogens